Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis (Q37940005)

25 August 2017

1 reference

title

Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis (English)

1 reference

25 August 2017

main subject

Pseudomonas aeruginosa

0 references

0 references

1 reference

2

1 reference

25 August 2017

Michael D Parkins

1

1 reference

25 August 2017

publication date

1 October 2011

1 reference

Expert Review of Respiratory Medicine

25 August 2017

published in

1 reference

25 August 2017

volume

5

1 reference

25 August 2017

issue

5

1 reference

25 August 2017

page(s)

609-622

1 reference

Update in cystic fibrosis 2008.

25 August 2017

cites work

1 reference

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

21 January 2018

1 reference

Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.

21 January 2018

1 reference

Microbiology of airway disease in a cohort of patients with cystic fibrosis

21 January 2018

1 reference

Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

21 January 2018

1 reference

Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition

21 January 2018

1 reference

Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis

21 January 2018

1 reference

A pipeline of therapies for cystic fibrosis

21 January 2018

1 reference

Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection

21 January 2018

1 reference

Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs

21 January 2018

1 reference

Formulation of aerosolized therapeutics

21 January 2018

1 reference

Microbiological and immunologic considerations with aerosolized drug delivery

21 January 2018

1 reference

Shifting patterns of inhaled antibiotic use in cystic fibrosis

21 January 2018

1 reference

Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations

21 January 2018

1 reference

Exacerbations in cystic fibrosis: 2 . prevention.

21 January 2018

1 reference

Inhaled Aztreonam Lysine for Chronic Airway Pseudomonas aeruginosa in Cystic Fibrosis

21 January 2018

1 reference

Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis

21 January 2018

1 reference

Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.

21 January 2018

1 reference

Inhaled antibiotic therapy: What drug? What dose? What regimen? What formulation?

21 January 2018

1 reference

Gentamicin inactivation in purulent exudates: role of cell lysis.

21 January 2018

1 reference

Efficacy of aerosolized tobramycin in patients with cystic fibrosis.

21 January 2018

1 reference

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

21 January 2018

1 reference

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease

21 January 2018

1 reference

High treatment burden in adults with cystic fibrosis: challenges to disease self-management

21 January 2018

1 reference

Adherence with tobramycin inhaled solution and health care utilization

21 January 2018

1 reference

Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis

21 January 2018

1 reference

Pharmacokinetics of intravenously administered tobramycin in normal volunteers and in renal-impaired and hemodialyzed patients.

21 January 2018

1 reference

Structural origins of aminoglycoside specificity for prokaryotic ribosomes

21 January 2018

1 reference

Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections

21 January 2018

1 reference

Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia

21 January 2018

1 reference

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

21 January 2018

1 reference

Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients

21 January 2018

1 reference

21 January 2018

Tobramycin: an overview

1 reference

Tobramycin: a review of its antibacterial and pharmacokinetic properties and therapeutic use

21 January 2018

1 reference

Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia.

21 January 2018

1 reference

Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration

21 January 2018

1 reference

Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis

21 January 2018

1 reference

Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring

21 January 2018

1 reference

Antibiotic blockade of neuromuscular function

21 January 2018

1 reference

Improved lung delivery from a passive dry powder inhaler using an Engineered PulmoSphere powder

21 January 2018

1 reference

Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology

21 January 2018

1 reference

Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety

21 January 2018

1 reference

Safety assessment of hydroxypropyl methylcellulose as a food ingredient

21 January 2018

1 reference

Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older

21 January 2018

1 reference

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

21 January 2018

1 reference

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial

21 January 2018

1 reference

Patient-reported respiratory symptoms in cystic fibrosis

21 January 2018

1 reference

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease

21 January 2018

1 reference

Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission

21 January 2018

1 reference

Microbial contamination of nebulizers in the home treatment of cystic fibrosis

21 January 2018

1 reference

Inhalation equipment hygiene: a belgian national survey.

21 January 2018

1 reference

Microbial contamination of nebulization solution and its measures

21 January 2018

1 reference

Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients

21 January 2018

1 reference

The choice of a compressor for the aerosolisation of tobramycin (TOBI) with the PARI LC PLUS reusable nebuliser.

21 January 2018

1 reference

Selection and properties of Pseudomonas aeruginosa variants resistant to beta-lactam antibiotics

21 January 2018

1 reference

Outpatient Treatment of Pseudomonas aeruginosa Bronchial Colonization with Long‐term Inhaled Colistin, Tobramycin, or Both in Adults without Cystic Fibrosis

21 January 2018

1 reference

Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment

21 January 2018

1 reference

Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis

21 January 2018

1 reference

Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.

21 January 2018

1 reference

Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy

21 January 2018

1 reference

Acute renal failure associated with inhaled tobramycin

21 January 2018

1 reference

Renal and vestibular toxicity due to inhaled tobramycin in a lung transplant recipient.

21 January 2018

1 reference

Aminoglycoside ototoxicity susceptibility in cystic fibrosis

21 January 2018

1 reference

Inhaled tobramycin-associated hearing loss in an adolescent with renal failure

21 January 2018

1 reference

In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells

21 January 2018

1 reference

Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa

21 January 2018

1 reference

Once-daily tobramycin in the treatment of adult patients with cystic fibrosis

21 January 2018

1 reference

Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.

21 January 2018

1 reference

An 18‐month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

21 January 2018

1 reference

Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis

21 January 2018

1 reference

Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects

21 January 2018

1 reference

Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa

21 January 2018

1 reference

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis

21 January 2018

1 reference

Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis

21 January 2018

1 reference

A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis

21 January 2018

1 reference

Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function

21 January 2018

1 reference

Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERS.11.56

1 reference

25 August 2017

1 reference